OOIR: Observatory of International Research

Papers

(The TQCC of Journal for Immunotherapy of Cancer is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	238
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	195
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	194
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	159
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	152
Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	150
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	139
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	138
Correction: A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer	137
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	137
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	132
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	128
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	123
TIPE2deletion improves the therapeutic potential of adoptively transferred NK cells	120
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	120
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	119
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	117
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	112
T-cell tolerant fraction as a predictor of immune-related adverse events	112
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	110
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	109
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	105
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	105
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	104
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	101

Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	99
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	98
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	94
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	93
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	93
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	92
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	92
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	91
Is immunotherapy safe and effective in patients with VEXAS syndrome?	89
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	89
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	88
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy	88
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	86
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	84
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	82
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	81
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	80
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	78
Commentary on oncolytic viruses: past, present, and future	78
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	77
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	76
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	76
Biomarkers for response to TIL therapy: a comprehensive review	75
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	75
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	75
iRECIST and atypical patterns of response to immuno-oncology drugs	74
Single-cell analysis reveals clonally expanded tumor-associated CD57⁺CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	74
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	74
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	73
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	72
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	70
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	70
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	70
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	69
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	69
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy	68
17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients	68
370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial	68
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	67
77 Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors	67
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for p	66
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	65
Addendum 1:Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	65
Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth	64
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC	64
Poor clinical outcomes and immunoevasive contexture in CD161⁺CD8⁺T cells barren human pancreatic cancer	64
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	64
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials	64
Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition	62
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs	62

Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis	62
Sulforaphane activates CD8⁺T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’	61
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechalle	60
Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity	60
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes	60
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch	60
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models	60
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity	59
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D	59
Targeting KDM4C enhances CD8⁺ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer	59
Correction: Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer	58
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types	58
11 Molecular characterization of naturally occurring colorectal and breast cancer in non-human primates to model human immunotherapeutic agents	58
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells	58
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function	58
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy	58
In memoriam: Soldano Ferrone, MD, PhD (1940–2023)	57
Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies	57
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression	57
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	57
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8⁺T cell-dependent antitumor immunity and abscopal effect after local irradiation	57
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	57
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	56
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy	56
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	56
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer	56
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer	55
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination	55
Accumulation of T-cell-suppressive PD-L1^highextracellular vesicles is associated with GvHD and might impact GvL efficacy	55
TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation	55
Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study	55
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy	55
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma	55
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer	55
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells	54
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications	54
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine	54
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation	54
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	54
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial	54
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia	54
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy	54
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy	54
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses	54
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion	54
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma	53
Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade	53
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes	53
PD-L1 gene amplification and focality: relationship with protein expression	53
Apoptosis: aJanus bifronsin T-cell immunotherapy	53
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	52
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer	52
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment	52
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	52
Id-neoantigen vaccine induces therapeutic CD8⁺T cells against multiple myeloma: H chain-loss escapees cause FLC MM	51
Modulating lipid metabolism improves tumor immunotherapy	51
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8⁺T cell cytotoxicity over BEMPEG+RT	51
Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma	51
286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)	51
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers	51
36 Digital Whole Slide Image (WSI) scoring is equivalent to microscope glass slide scoring for evaluation of programmed death-ligand 1 (PD-L1) expression across multiple tumor indications	50
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)	50
Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers	50
20 Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy	50
Correction: Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel	50
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy	50
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report	49
Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events	49
291 Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity	49
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity	49
CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer	49
Correction: Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?	49
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity	49
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer	48
Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer	48
TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy	48
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders	48
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer	48
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies	48
Correction: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma	47

Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody	47
Correction: Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy	47
322 Melanoma-intrinsic hypoxia-inducible factor-1α results in diminished T cell accumulation within the tumor microenvironment	47
19 Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST	47
Rescuing natural killer cells from the cancer wilderness	46
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma	46
Spatial immune remodeling of the liver metastases: discovering the path to antimetastatic therapy	46
Exploring molecular imaging to investigate immune checkpoint inhibitor-related toxicity	46
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases	46
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors	46
Guidelines for immunological analyses following focused ultrasound treatment	46
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models	46
45 AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells	46
Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma	45
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors	45
Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis	45
Serotonin receptor 5-HT_2Aas a potential target for HCC immunotherapy	45
Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer	45
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models	45
Potentiation of cancer immunogenicity by targeting PARP	45
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens	45
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients withBRAFV600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)	45
Author response to Zhang et al	44
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade	44
Neoantigens as potential vaccines in hepatocellular carcinoma	44
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy	44
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression	44
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome	44
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer	44
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chhedaet al	44
Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy	44
52 Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI)	44
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma	43
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation	43
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors	43
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer	43
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling	43
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade	43
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization	43
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma	43
TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8⁺T cell and XCR1⁺dendritic cell spatial co-localization	43
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation	42
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors	42
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a ph	42
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy	42
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma	42
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma	42
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex	42
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience	42
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial	42
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG	41
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy	41
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors	41
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer	41
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells	41
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial	41
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)	41
292 Ex vivo profiling of PD-1 blockade using an organotypic tissue slice model in solid tumors	40
Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition	40
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity	40
212 Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates	40
64 A cloning and expression system of the neoantigen-specific TCRs from tumor-infiltrating lymphocytes by single-cell sequencing of paired TCRα and TCRβ chains	40
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses	40
Correction: MRI techniques for immunotherapy monitoring	40
Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy	40
Correction: Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer	39
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use	39
Letter to the editor: transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	39
Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin	39
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C	39
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab	39
318 Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance	39
Paired single-B-cell transcriptomics and receptor sequencing reveal activation states and clonal signatures that characterize B cells in acute myeloid leukemia	39
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses	39
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma	39
NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases	39
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment	39
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins	39
CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors	38
Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer	38
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive	38
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells	38
Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression	38
Specific inhibitor to KRAS^G12C induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy	38
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma	38
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC	38
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis	38
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8⁺ T cells	38
Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry	37
CD56^brightcytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells	37
Selective BCL-2 inhibitor triggers STING-dependent antitumor immunity via inducing mtDNA release	37
TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma	37
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes	37
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma	37
Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma	37